Nasdaq · Healthcare
Twist Bioscience Corp (TWST)
As-reported financials and recent SEC filings for Twist Bioscience Corp, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$376.6M
Net income
$-77.7M
Net margin
-20.6%
Diluted EPS
$-1.30
ROE
-16.4%
P/E (TTM)
—
Market cap
$6.22B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $376.6M | $313.0M | $245.1M | $203.6M | $132.3M |
| Gross profit | $191.0M | $133.3M | $89.7M | $84.2M | $51.7M |
| Operating income | $-136.3M | $-220.8M | $-217.2M | $-234.8M | $-152.7M |
| Net income | $-77.7M | $-208.7M | $-204.6M | $-217.9M | $-152.1M |
| Diluted EPS | $-1.30 | $-3.60 | $-3.60 | $-4.04 | $-3.15 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-26
View on EDGAR →42026-06-26
View on EDGAR →1442026-06-25
View on EDGAR →1442026-06-24
View on EDGAR →42026-06-24
View on EDGAR →42026-06-24
View on EDGAR →42026-06-24
View on EDGAR →1442026-06-22
View on EDGAR →Go deeper on TWST
Search Twist Bioscience Corp’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.